Literature DB >> 7682335

Preparation and reactivities of anti-porcine CD44 monoclonal antibodies.

H Yang1, A Hutchings, R M Binns.   

Abstract

Five monoclonal antibodies (MoAbs) were raised against porcine soluble CD44. The MoAbs recognized the same antigen on the surface of porcine lymphocytes as was recognized by anti-human CD44 MoAb Hermes-1, but identified five different epitopes. They bound to most porcine leucocytes but not to red cells. The epitopes were susceptible to treatment with papain or bromelain, whereas trypsinization of porcine leucocytes only reduced the antigen density. The epitopes seem to be co-expressed among various lymphoid tissues. The MoAbs also cross-reacted to various degrees with leucocytes of humans, dogs, sheep, cattle, goats and horses, suggesting that the corresponding epitopes are differentially conserved among species.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682335     DOI: 10.1111/j.1365-3083.1993.tb03324.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  4 in total

1.  Expression of CD44 isoforms during bleomycin-or radiation-induced pulmonary fibrosis in rats and mini-pigs.

Authors:  M Kasper; A Bierhaus; A Whyte; R M Binns; D Schuh; M Müller
Journal:  Histochem Cell Biol       Date:  1996-03       Impact factor: 4.304

2.  Preparation of monoclonal anti-porcine CD3 antibodies and preliminary characterization of porcine T lymphocytes.

Authors:  H Yang; C A Oura; P A Kirkham; R M Parkhouse
Journal:  Immunology       Date:  1996-08       Impact factor: 7.397

3.  Phenotypic classification of porcine lymphocyte subpopulations in blood and lymphoid tissues.

Authors:  H Yang; R M Parkhouse
Journal:  Immunology       Date:  1996-09       Impact factor: 7.397

4.  Major long-term changes in gamma delta T-cell receptor-positive and CD2+ T-cell subsets after neonatal thymectomy in the pig: a longitudinal study lasting nearly 2 years.

Authors:  S T Licence; R M Binns
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.